Phase IB Trial of Induction Nivolumab or Nivolumab/Ipilimumab Prior to Concurrent Chemoradiation Plus Nivolumab in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- 11 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2019 Results (n=16) presented at the 2019 Gastrointestinal Cancers Symposium
- 08 Jan 2019 Planned End Date changed from 1 Feb 2022 to 1 Feb 2025.